Low-dose salvage brachytherapy after first-line EBRT

The potential to use some form of second-line radiation therapy after failure of first-line radiation therapy has long been intriguing, and is highly dependent on the dose and precise volume of the target of first-line radiation therapy. … READ MORE …

Guidelines and the current treatment of mCRPC

The December 1 issue of The ASCO Post contains two articles that will be of interest to many patients with progressive disease and their family members. … READ MORE …

Innocrin Pharmaceuticals moving VT-464 into Phase II portion of Phase I/II trial

Innocrin Pharmaceuticals has been conducting the Phase I portion of a Phase I /II trial of VT-464, a CYP17 lyase inhibitor, in men with treatment-naïve CRPC and in CRPC patients who have failed prior therapy with abiraterone, enzalutamide, and/or chemotherapy. … READ MORE …

“The punishing cost of cancer care”

A post with the above title by Dr. Mikkael Sekeres of the Cleveland Clinic appeared yesterday on the “Well” blog of The New York Times web site. The patient referred to probably doesn’t have prostate cancer … but the tale is one that too many prostate cancer patients may now have to face.

Outcomes after intensive ADT and surgery in high-risk men with localized disease

The initial results of a small Phase II trial of androgen deprivation therapy (ADT) + abiraterone acetate prior to surgery in high-risk patients have now been published. … READ MORE …

Other prostate cancer presentations at the winter 2014 SUO meeting

The following is a list of the most significant prostate cancer presentations given at the winter meeting of the Society for Urologic Oncology (SUO) in Washington, DC, last week. … READ MORE …

Over-treatment of older men with life expectancies < 10 years

According to a paper newly published in Cancer, “Men aged < 80 years at diagnosis who have life expectancies < 10 years often receive aggressive treatment for low-risk and intermediate-risk prostate cancer, mostly with radiation therapy.” … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,182 other followers